​
​

Entrada Therapeutics (TRDA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

TRDA Stock Forecast

Entrada Therapeutics stock forecast is as follows: an average price target of $20.00 (represents a 11.54% upside from TRDA’s last price of $17.93) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

TRDA Price Target

The average price target for Entrada Therapeutics (TRDA) is $20.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $20.00 to $20.00. This represents a potential 11.54% upside from TRDA's last price of $17.93.

TRDA Analyst Ratings

Buy

According to 3 Wall Street analysts, Entrada Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for TRDA stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Entrada Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 06, 2024Boobalan PachaiyappanH.C. Wainwright$20.00$18.0210.96%11.54%
Jun 25, 2024Raghuram SelvarajuH.C. Wainwright$18.00$14.2426.40%0.39%
Row per page
Go to

The latest Entrada Therapeutics stock forecast, released on Nov 06, 2024 by Boobalan Pachaiyappan from H.C. Wainwright, set a price target of $20.00, which represents a 10.96% increase from the stock price at the time of the forecast ($18.02), and a 11.54% increase from TRDA last price ($17.93).

Entrada Therapeutics Price Target by Period

1M3M12M
# Anlaysts112
Avg Price Target$20.00$20.00$19.00
Last Closing Price$17.93$17.93$17.93
Upside/Downside11.54%11.54%5.97%

In the current month, the average price target of Entrada Therapeutics stock is $20.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 11.54% increase as opposed to Entrada Therapeutics's last price of $17.93. This month's average price target is down 0.00% compared to last quarter, and up 5.26% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Aug 14, 2024Cowen & Co.BuyBuyHold
Jun 25, 2024H.C. WainwrightBuyBuyHold
Jun 24, 2024Cowen & Co.BuyBuyHold
Nov 22, 2023William BlairOutperformOutperformHold
Row per page
Go to

Entrada Therapeutics's last stock rating was published by Cowen & Co. on Aug 14, 2024. The company gave TRDA a "Buy" rating, the same as its previous rate.

Entrada Therapeutics Financial Forecast

Entrada Therapeutics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23
Revenue------------$41.85M$43.73M-$25.26M
Avg Forecast$14.11M$7.05M$14.11M$14.11M$9.73M$12.38M$12.38M$12.38M$13.34M$12.32M$51.86M$14.98M$23.69M$9.60M$9.78M$7.00M
High Forecast$16.94M$8.47M$16.94M$16.94M$11.68M$14.87M$14.87M$14.31M$15.18M$14.79M$62.27M$14.98M$31.08M$9.60M$11.74M$8.40M
Low Forecast$11.75M$5.87M$11.75M$11.75M$8.10M$10.31M$10.31M$10.44M$11.50M$10.26M$43.19M$14.98M$12.01M$9.60M$8.14M$5.83M
# Analysts1111111331224222
Surprise %------------1.77%4.56%-3.61%

Entrada Therapeutics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $14.98M, with a low forecast of $14.98M, and a high forecast of $14.98M. TRDA's average Quarter revenue forecast represents a -64.21% decrease compared to the company's last Quarter revenue of $41.85M (Dec 23).

Entrada Therapeutics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23
# Analysts1111111331224222
EBITDA------------$5.64M$14.01M-$-5.78M
Avg Forecast$11.28M$5.64M$11.28M$11.28M$7.78M$9.90M$9.90M$9.90M$10.67M$9.85M$41.46M$11.97M$18.94M$7.67M$7.82M$5.60M
High Forecast$13.54M$6.77M$13.54M$13.54M$9.34M$11.89M$11.89M$11.44M$12.14M$11.83M$49.78M$11.97M$24.85M$7.67M$9.38M$6.72M
Low Forecast$9.39M$4.70M$9.39M$9.39M$6.48M$8.24M$8.24M$8.34M$9.20M$8.20M$34.53M$11.97M$9.61M$7.67M$6.51M$4.66M
Surprise %------------0.30%1.83%--1.03%

2 analysts predict TRDA's average Quarter EBITDA for Mar 24 to be $11.97M, with a high of $11.97M and a low of $11.97M. This is 112.27% upper than Entrada Therapeutics's previous annual EBITDA (Dec 23) of $5.64M.

Entrada Therapeutics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23
# Analysts1111111331224222
Net Income------------$-9.54M$35.46M-$-6.67M
Avg Forecast$-34.00M$-38.10M$-30.11M$-29.11M$-37.07M$-32.42M$-31.12M$-30.31M$-27.63M$-29.58M$14.68M$-24.13M$-6.84M$-29.86M$-28.03M$-26.46M
High Forecast$-26.61M$-29.82M$-23.57M$-22.78M$-29.02M$-25.37M$-24.36M$-27.28M$-27.22M$-23.15M$14.69M$-18.89M$20.53M$-23.37M$-21.94M$-20.71M
Low Forecast$-42.87M$-48.04M$-37.97M$-36.70M$-46.75M$-40.88M$-39.24M$-32.58M$-28.45M$-37.30M$14.67M$-30.43M$-51.81M$-37.65M$-35.34M$-33.36M
Surprise %------------1.39%-1.19%-0.25%

Entrada Therapeutics's average Quarter net income forecast for Dec 23 is $-6.84M, with a range of $-51.81M to $20.53M. TRDA's average Quarter net income forecast represents a -119.30% decrease compared to the company's last Quarter net income of $35.46M (Sep 23).

Entrada Therapeutics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23
# Analysts1111111331224222
SG&A------------$8.65M$7.53M-$7.94M
Avg Forecast$11.99M$6.00M$11.99M$11.99M$8.27M$10.52M$10.52M$10.52M$11.34M$10.47M$44.08M$12.73M$20.14M$8.16M$8.31M$5.95M
High Forecast$14.40M$7.20M$14.40M$14.40M$9.93M$12.64M$12.64M$12.17M$12.91M$12.58M$52.93M$12.73M$26.42M$8.16M$9.98M$7.14M
Low Forecast$9.99M$4.99M$9.99M$9.99M$6.89M$8.76M$8.76M$8.87M$9.78M$8.72M$36.71M$12.73M$10.21M$8.16M$6.92M$4.96M
Surprise %------------0.43%0.92%-1.33%

Entrada Therapeutics's average Quarter SG&A projection for Mar 24 is $12.73M, based on 2 Wall Street analysts, with a range of $12.73M to $12.73M. The forecast indicates a 47.15% rise compared to TRDA last annual SG&A of $8.65M (Dec 23).

Entrada Therapeutics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23
# Analysts1111111331224222
EPS------------$-0.29$1.07-$-0.21
Avg Forecast$-0.84$-0.94$-0.74$-0.72$-0.91$-0.80$-0.77$-0.75$-0.68$-0.73$0.36$-0.59$-0.17$-0.73$-0.69$-0.65
High Forecast$-0.65$-0.73$-0.58$-0.56$-0.71$-0.62$-0.60$-0.67$-0.67$-0.57$0.36$-0.46$0.51$-0.58$-0.54$-0.51
Low Forecast$-1.06$-1.18$-0.93$-0.90$-1.15$-1.01$-0.97$-0.80$-0.70$-0.92$0.36$-0.75$-1.28$-0.93$-0.87$-0.82
Surprise %------------1.72%-1.46%-0.32%

According to 4 Wall Street analysts, Entrada Therapeutics's projected average Quarter EPS for Dec 23 is $-0.17, with a low estimate of $-1.28 and a high estimate of $0.51. This represents a -115.74% decrease compared to TRDA previous annual EPS of $1.07 (Sep 23).

Entrada Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PMVPPMV Pharmaceuticals$1.57$18.001046.50%Buy
PEPGPepGen$4.40$29.50570.45%Buy
MOLNMolecular Partners$5.20$29.00457.69%Buy
OPTOpthea$3.28$14.00326.83%Buy
VIGLVigil Neuroscience$3.05$11.00260.66%Buy
LRMRLarimar Therapeutics$6.08$20.33234.38%Buy
ELYMEliem Therapeutics$5.11$13.00154.40%Buy
CGEMCullinan Oncology$12.58$31.50150.40%Buy
TYRATyra Biosciences$15.87$31.75100.06%Buy
PHVSPharvaris$20.50$39.6793.51%Buy
EWTXEdgewise Therapeutics$31.95$45.0040.85%Buy
THRDThird Harmonic Bio$11.62$16.1538.98%Buy
CNTACentessa Pharmaceuticals$16.74$23.2538.89%Buy
CRNXCrinetics Pharmaceuticals$56.07$70.1425.09%Buy
IRONDisc Medicine$62.55$72.5015.91%Buy
TRDAEntrada Therapeutics$17.93$20.0011.54%Buy

TRDA Forecast FAQ

Is Entrada Therapeutics a good buy?

Yes, according to 3 Wall Street analysts, Entrada Therapeutics (TRDA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of TRDA's total ratings.

What is TRDA's price target?

Entrada Therapeutics (TRDA) average price target is $20 with a range of $20 to $20, implying a 11.54% from its last price of $17.93. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Entrada Therapeutics stock go up soon?

According to Wall Street analysts' prediction for TRDA stock, the company can go up by 11.54% (from the last price of $17.93 to the average price target of $20), up by 11.54% based on the highest stock price target, and up by 11.54% based on the lowest stock price target.

Can Entrada Therapeutics stock reach $30?

TRDA's average twelve months analyst stock price target of $20 does not support the claim that Entrada Therapeutics can reach $30 in the near future.

What is Entrada Therapeutics's current price target trend?

1 Wall Street analyst forecast a $20 price target for Entrada Therapeutics (TRDA) this month, up 11.54% from its last price of $17.93. Compared to the last 3 and 12 months, the average price target increased by 11.54% and increased by 5.97%, respectively.

What are Entrada Therapeutics's analysts' financial forecasts?

Entrada Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $46.87M (high $55.72M, low $39.16M), average EBITDA is $37.47M (high $44.55M, low $31.31M), average net income is $-131M (high $-106M, low $-159M), average SG&A $39.84M (high $47.37M, low $33.29M), and average EPS is $-3.223 (high $-2.61, low $-3.925). TRDA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $49.37M (high $59.28M, low $41.11M), average EBITDA is $39.47M (high $47.39M, low $32.87M), average net income is $-131M (high $-103M, low $-166M), average SG&A $41.97M (high $50.39M, low $34.95M), and average EPS is $-3.232 (high $-2.53, low $-4.076).

Did the TRDA's actual financial results beat the analysts' financial forecasts?

Based on Entrada Therapeutics's last annual report (Dec 2023), the company's revenue was $129.01M, beating the average analysts forecast of $50.06M by 157.71%. Apple's EBITDA was $-3.162M, missing the average prediction of $40.02M by -107.90%. The company's net income was $-6.685M, missing the average estimation of $-91.189M by -92.67%. Apple's SG&A was $32.29M, missing the average forecast of $42.56M by -24.12%. Lastly, the company's EPS was $-0.0002, missing the average prediction of $-2.244 by -99.99%. In terms of the last quarterly report (Dec 2023), Entrada Therapeutics's revenue was $41.85M, beating the average analysts' forecast of $23.69M by 76.66%. The company's EBITDA was $5.64M, missing the average prediction of $18.94M by -70.21%. Entrada Therapeutics's net income was $-9.544M, beating the average estimation of $-6.843M by 39.47%. The company's SG&A was $8.65M, missing the average forecast of $20.14M by -57.03%. Lastly, the company's EPS was $-0.29, beating the average prediction of $-0.168 by 72.19%